Metoclopramide

As a classic clinical digestive system prokinetic and antiemetic drug, metoclopramide is a dopamine D2 receptor antagonist that also has 5-hydroxytryptamine 4 receptor agonist effects. It can act on the chemoreceptor trigger zone of the medulla oblongata to raise the threshold, while promoting the movement of the stomach and upper intestinal segments and accelerating gastric emptying. It is widely used in clinical practice for the treatment of nausea and vomiting caused by radiotherapy and chemotherapy, surgery, craniocerebral injury and other reasons, and can also be used for symptomatic management of digestive tract diseases such as reflux esophagitis, bile reflux gastritis, and functional gastric retention. Its applicable population covers adults and children who meet the medication indications, and it is a basic antiemetic drug routinely stocked in primary medical institutions and tertiary hospitals.

At present, the global market size of metoclopramide is stable at around USD 420 million, and the annual sales in the domestic market are approximately RMB 780 million, with a compound growth rate of 3.2% in the past three years. As a mature product that has been on the market for more than 60 years, it has low generic barriers. There are more than 20 domestic API manufacturers and over 300 preparation approvals. After the centralized procurement, the winning bid price of ordinary tablets has dropped to about RMB 0.1 per tablet, and the accessibility at the primary level has been greatly improved. The current market competition is dominated by domestic generic pharmaceutical enterprises, with the original research product accounting for less than 5%. The overall pattern is stable, and the API supply side has been basically localized.

The original research enterprise of metoclopramide is Sanofi Aventis, and the original brand name is Primperan. The core compound patent expired globally in 1973. At present, the mainstream dosage forms include 10mg conventional tablets and 10mg/1ml injections. Among them, the original 10mg tablets and 10mg/1ml injections have been included in the FDA Reference Listed Drug Catalog, and the domestic 10mg tablets have been included in the *Catalog of Reference Preparations for Chemical Drugs (Third Batch)*. Up to now, the metoclopramide APIs of 37 domestic enterprises have been registered with the CDE (29 in A status). Domestic metoclopramide tablets and injections have been approved for marketing for decades, with sufficient supply. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for metoclopramide API. Most products are available from stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All reference standards meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the use needs of pharmaceutical enterprises in various scenarios such as quality research and consistency evaluation.